Joined May 2014
- Tweets1.1K
- Following392
- Followers1.5K
- Likes670
see the effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY study - dom-pubs-onlinelibrary-wiley…
Peter Rossing retweeted
"We do much more complicated things, we use much more dangerous drugs for other conditions that don't deliver like this"
"And if you don't do it, you're likely to become obsolete... because someone else will"
Professor Tuttle with a #kidneywk call to arms 🔥🔥🔥 #kidneycompass
Last but certainly not least, Tuttle on FLOW and nephrology’s role in prescribing GLP-1s in kidney disease:
hcplive.com/view/kidney-comp…
Peter Rossing retweeted
Dear all,
I will defend my Ph.D. on Friday, November 8th at 2:30 PM at Herlev Hospital, and you are all more than welcome to drop by and listen in.
// Marie
@Stenodiabetes @HerlevGentofte @UCPH_Research @SUHhospital @RikkeBorg @FrederikPersson @DitteHansen7 @IBressendorff
No effects of probiotics and fibers on markers of nephropathy, inflammation and intestinal barrier in T1D during a 12w study
sciencedirect.com/science/ar… @Stenodiabetes @buur_stougaard
Endothelial dysfunction markers syndecan-1 and thrombomodulin are associated with higher albuminuria levels in t2d without CVD pubmed.ncbi.nlm.nih.gov/3940…
Severely increased albuminuria at screening is a powerful criterion for selecting persons with T1D at high risk of kidney function decline.
pubmed.ncbi.nlm.nih.gov/3942…
Peter Rossing retweeted
Our latest NUDGE trial just published in @JAMA_current 👇
Led by the brilliant @niklasdj1, in collaboration with amazing colleagues from @SSI_dk @harvardmed @Region_Midt and many more.
@CTCPR_ continues to provide important evidence regarding how we can improve public health
Simple, scalable, and cost-efficient electronic letter strategies, used in this study to encourage flu vaccinations, may have substantial public health implications.
ja.ma/480pTr7
Peter Rossing retweeted
Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial | @NatureMedicine Spiro was often discontinued and no effect on outcome nature.com/articles/s41591-0…
Peter Rossing retweeted
The first simpub from the @CTCPR_ team during #ESC2024. The NUDGE-FLU-2 trial results in @NatureMedicine lead by @niklasdj1 👇
Electronic nudges for sustained influenza vaccination uptake in older adults (>65): the nationwide randomized NUDGE-FLU-2 trial
nature.com/articles/s41591-0…
Peter Rossing retweeted
Lovely final slide of the FINEHEART presentation from @mvaduganathan dedicated to the late Professor George Bakris #ESCCongress
See the FINE-HEART
all phase 3 studies with finerenone compiled
rdcu.be/dSC7n
See Prof Pratley share Insights from the FLOW Trial | ESC 2024 youtu.be/jCmyx8_4nlk?si=bxaQ… via @YouTube
Bnefit of semaglutide in heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
sciencedirect.com/science/ar…
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial academic.oup.com/eurheartj/a…
Swe the amazing Effects of Semaglutide on Heart Failure Outcomes in Diabetes and CKD sciencedirect.com/science/ar… @Stenodiabetes
Effects of Dapagliflozin in Patients with Membranous Nephropathy : looking good, but we will need to learn more
pubmed.ncbi.nlm.nih.gov/3914…
We are looking for a Statistician for the Epidemiological team in Complications Research @steno diabetes center copenhagen
shar.es/ag56iQ
Effects of Dapagliflozin in Patients with Membranous Nephropathy looks promising!
karger.com/gdz/article/4/1/1…
Peter Rossing retweeted
*Breaking* P3 #FINEARTSHF meets its primary endpoint (CVd+total HF events)!
Non-steroidal MRA finerenone "demonstrates definitive CV benefits" in HFmrEF & HFpEF
Looking forward to presenting full results at #ESCCongress alongside @scottdsolomon @PSJhund
bayer.com/media/en-us/finere…
